NIAID Site Search

I am announcing today that I will be stepping down from the positions of Director of the National Institute of Allergy and Infectious Diseases (NIAID) and Chief of the NIAID Laboratory of Immunoregulation, as well as the position of Chief Medical Advisor to President Joe Biden. I will be leaving these positions in December of this year to pursue the next chapter of my career.

Published: August 22, 2022

Once considered a potentially static field of medicine, the discipline of studying infectious diseases has proven to be dynamic as emerging and reemerging infectious diseases present continuous challenges, Anthony S. Fauci, M.D., writes in a perspective in The New England Journal of Medicine. In the piece, Dr. Fauci, who since 1984 has directed the National Institute of Allergy and Infectious

Published: November 28, 2022

During the first full day of research presentations at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI), HIV.gov spoke with Dr. Carl Dieffenbach, Director of the Division of AIDS at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), about some initial highlights, including the opening session that featured a lecture by Dr. Anthony Fauci and several studies

Published: February 22, 2023

Lawrence A. Tabak, D.D.S., Ph.D., acting director for the National Institutes of Health (NIH), has named Jeanne M. Marrazzo, M.D., as director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID).

Published: August 2, 2023

NIAID Acting Director Dr. Hugh Auchincloss provided updates on HIV/AIDS, malaria, Ebola, a promising Marburg vaccine, universal flu vaccine efforts, non-viral asthma attacks, monoclonal antibodies to target Epstein-Barr virus, and human antibody response to vaccinations.

Published: February 15, 2023

NIH Opening Statement Senate LHHS FY 2019 Hearing: Prepared statement of Lawrence A. Tabak, D.D.S., PH.D., Principal Deputy Director, Office of the Director

Last Reviewed: August 16, 2018

A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods, a National Institutes of Health clinical trial has found. This population has been underrepresented in previous clinical trials of asthma therapeutics. The findings were published

Published: August 10, 2022

This document provides an overview of research and training programs opportunities for 2022-2023 available through the Division of Intramural Research.

Last Reviewed: November 3, 2022

Jordan Report: Accelerated Development of Vaccines (2002) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2002

Jordan Report: Accelerated Development of Vaccines (2007) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: August 6, 2019

NIH Strategic Plan and Research Agenda for Medical Countermeasures Against Chemical Threats

Last Reviewed: May 18, 2022

The 202nd meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened virtually at 10:30 a.m. on Monday, September 12, 2022. Dr. Anthony S. Fauci, Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair. In accordance with the provisions of Public Law 92-463, the meeting was open to the public from 10:30 a.m. to 11:44 a.m. and from 1

Last Reviewed: January 27, 2023

NIH strategic plan to develop medical countermeasures against possible terrorist attacks involving radioactive materials.

Last Reviewed: December 5, 2019

This report outlines the ethical considerations for zika virus human challenge trials and provides recommendations.

Last Reviewed: November 26, 2019

Sample application from Jose M. Galarza, Ph.D., for Small Business Technology Transfer (STTR) grant (R43).

Last Reviewed: November 25, 2022

This document provides a summary of the NIAID Expert Panel Review on Medical Chemical Defense Research on March 19, 2003.

Last Reviewed: March 19, 2003

The 203 rd meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened virtually at 10:30 a.m. on Monday, January 30, 2023. Dr. Hugh Auchincloss, Acting Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair. In accordance with the provisions of Public Law 92-463, the meeting was open to the public from 10:30 a.m. to 11:51 a.m. and

Last Reviewed: February 5, 2024

The 206 th meeting of the National Advisory Allergy and Infectious Diseases Council (NAAIDC) convened virtually at 10:30 a.m. on Tuesday, January 30, 2024. Dr. Jeanne Marrazzo, Director, National Institute of Allergy and Infectious Diseases (NIAID) presided as chair. In accordance with the provisions of Public Law 92-463, the meeting was open to the public from 10:30 a.m. to 11:45 a.m. and from 1

Last Reviewed: May 21, 2024